- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03764319
Low Frequency, Ultra-low Tidal Volume Ventilation in Patients With ARDS and ECMO
Low Frequency, Ultra-low Tidal Volume Ventilation in Patients With Severe Acute Respiratory Distress Syndrome and Extracorporeal Membrane Oxygenation: a Prospective, Randomized, Clinical Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The aim of this study is to assess the effect of a rigorous low breathing frequency and ultra-low tidal volume ventilation strategy on clinical outcome, compared to standard ventilator settings following the recent guidelines in patients with severe ARDS treated with ECMO.
The hypothesis is that a low breathing frequency and ultra-low tidal volume ventilation strategy is more protective for the ARDS challenged lung and reduces the duration of mechanical ventilation and so increases the ventilator free days in patients with severe ARDS treated with ECMO.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Vienna, Austria, 1090
- Medical University of Vienna - Division of General Anaesthesia and Intensive Care Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Moderate to severe ARDS - Partial pressure of oxygen/Fraction of inspired oxygen (PaO2/FiO2) < 200 mmHg
- ECMO < 24 hours in situ
- Gender-matched
- Age-matched
Exclusion Criteria:
- BMI > 40
- Expected weaning of ECMO < 3 days (postoperative ECMO)
- Combustion
- Restrictive chest wall impairment
- Pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Intervention group
Ultra-protective ventilator settings in patients with ARDS and ECMO.
|
4-5 Breaths per minute; 14-16 cmH2O Positive endexpiratory pressure (PEEP) (adjust PEEP to 23 < Plateau pressure < 25 cmH2O); 23-25 cmH2O Plateau pressure (adjust to not exceed Tidal volume > 4 mL/kg Predicted body weight (PBW)); < 4mL/kg PBW Tidal volume; 1:5 Inspiration:Expiration (I:E)
|
ACTIVE_COMPARATOR: Control group
Standard ventilator settings in patients with ARDS and ECMO.
|
12-25 Breaths per minute; 8-12 cmH2O PEEP; max.
35 cmH2O Plateau pressure
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Ventilator free days
Time Frame: Immediately after initiation of ECMO up to 28 days
|
Ventilator free days
|
Immediately after initiation of ECMO up to 28 days
|
Time from randomization to fulfillment of extubation criteria
Time Frame: Immediately after initiation of ECMO up to 28 days
|
Time from randomization (initiation of ECMO) to fulfillment of the extubation criteria:
|
Immediately after initiation of ECMO up to 28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total time of mechanical ventilation
Time Frame: Start of mechanical ventilation up to 28 days
|
Total time of mechanical ventilation
|
Start of mechanical ventilation up to 28 days
|
28 day mortality
Time Frame: Immediately after initiation of ECMO up to 28 days
|
Mortality from initiation of ECMO till day 28 after initiation of ECMO
|
Immediately after initiation of ECMO up to 28 days
|
One year mortality
Time Frame: Immediately after initiation of ECMO up to one year
|
Mortality from initiation of ECMO till one year after initiation of ECMO
|
Immediately after initiation of ECMO up to one year
|
Incidence of reintubation
Time Frame: Immediately after initiation of ECMO up to 28 days
|
Incidence of reintubation
|
Immediately after initiation of ECMO up to 28 days
|
Length of ICU stay
Time Frame: Immediately after initiation of ECMO
|
Length of ICU stay
|
Immediately after initiation of ECMO
|
Evaluation of RAS, ACE, ACE2.
Time Frame: 2 months
|
Analyses of leftover blood.
Renin angiotensin system (RAS) and Angiotensin converting enzyme (ACE) evaluation.
|
2 months
|
Evaluation of Cytokines in pg/ml
Time Frame: 2 months
|
IL-6, IL-8, TNFR1, RAGE, Protein C
|
2 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Roman Ullrich, Ao.Univ.Prof., Department of Anesthesia and Intensive Care
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MUVienna ARDS-ECMO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Respiratory Tract Diseases
-
Vakzine Projekt Management GmbHFGK Clinical Research GmbHUnknownInfection, Respiratory TractGermany
-
University of Colorado, DenverBiofireCompletedAcute Respiratory Infection | Lower Respiratory Tract Illness | Respiratory Pathogens | Upper Respiratory Tract IllnessUnited States
-
Zambon SpACompleted
-
PfizerTerminatedRespiratory Tract InfectionUnited States, Australia
-
GlaxoSmithKlineCompletedInfections, Respiratory TractGermany
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompletedInfections, Respiratory TractUnited States
-
GlaxoSmithKlineCompletedInfections, Respiratory TractAustralia
-
GlaxoSmithKlineCompletedInfections, Respiratory Tract
-
PfizerCompletedRespiratory Tract InfectionUnited States, Netherlands, Spain, Korea, Republic of, Denmark, Taiwan, Australia, Mexico, Canada, Japan, Finland, Argentina, Brazil, Chile, Gambia, New Zealand, Philippines, South Africa
Clinical Trials on Ultra-protective ventilator settings
-
University Hospital of North NorwayCambridge University Hospitals NHS Foundation Trust; Hôpital de la Croix-RousseCompletedVentilator-Induced Lung Injury | Acute Brain Injury | Cerebrovascular CirculationNorway
-
University of Medicine and Dentistry of New JerseyTerminatedAcute Respiratory Distress SyndromeUnited States
-
Respironics, California, Inc.Terminated
-
Laval UniversityCompletedCardiac Surgery | Mechanically Ventilated Patients
-
University of AarhusAarhus University HospitalCompletedFluid Overload | HypovolemiaDenmark
-
Ligue Pulmonaire GenevoiseCompletedChronic Obstructive Pulmonary DiseaseSwitzerland
-
University Hospital Schleswig-HolsteinCompleted
-
Dr. Negrin University HospitalAsociación Científica Pulmón y Ventilación MecánicaCompleted
-
Gaziosmanpasa Research and Education HospitalCompleted
-
University of Vermont Medical CenterNot yet recruitingObesity | Surgery | Anesthesia | Mechanical Ventilation | Echocardiography, TransesophagealUnited States